Repros Therapeutics has begun two clinical studies comparing Androxal to the leading U.S. testosterone replacement therapy. Investigational Review Board approval has been obtained for several of the study sites and an investigator meeting and shipment of drug is scheduled for next week. Several sites have begun pre-screening subjects. The FDA has previously indicated that head-to-head studies could be conducted against approved testosterone products to establish claims for labeling purposes with...